Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.
Helios Health Institute, Real World Evidence and Health Technology Assessment, Berlin, Germany.
Curr Cardiol Rep. 2024 Aug;26(8):801-814. doi: 10.1007/s11886-024-02085-8. Epub 2024 Jul 8.
Cardiac pacing has evolved in recent years currently culminating in the specific stimulation of the cardiac conduction system (conduction system pacing, CSP). This review aims to provide a comprehensive overview of the available literature on CSP, focusing on a critical classification of studies comparing CSP with standard treatment in the two fields of pacing for bradycardia and cardiac resynchronization therapy in patients with heart failure. The article will also elaborate specific benefits and limitations associated with CSP modalities of His bundle pacing (HBP) and left bundle branch area pacing (LBBAP).
Based on a growing number of observational studies for different indications of pacing therapy, both CSP modalities investigated are advantageous over standard treatment in terms of narrowing the paced QRS complex and preserving or improving left ventricular systolic function. Less consistent evidence exists with regard to the improvement of heart failure-related rehospitalization rates or mortality, and effect sizes vary between HBP and LBBAP. LBBAP is superior over HBP in terms of lead measurements and procedural duration. With regard to all reported outcomes, evidence from large scale randomized controlled clinical trials (RCT) is still scarce. CSP has the potential to sustainably improve patient care in cardiac pacing therapy if patients are appropriately selected and limitations are considered. With this review, we offer not only a summary of existing data, but also an outlook on probable future developments in the field, as well as a detailed summary of upcoming RCTs that provide insights into how the journey of CSP continues.
近年来心脏起搏技术不断发展,目前正聚焦于心电激动系统的精准刺激(心脏传导系统起搏,CSP)。本综述旨在对 CSP 的现有文献进行全面综述,重点对 CSP 与标准治疗在心动过缓起搏和心力衰竭心脏再同步治疗这两个领域的对比研究进行批判性分类。本文还将详细阐述希氏束起搏(HBP)和左束支区域起搏(LBBAP)这两种 CSP 模式的具体获益和局限性。
基于越来越多针对不同起搏治疗适应证的观察性研究,这两种 CSP 模式在缩小起搏 QRS 波群和保留或改善左心室收缩功能方面均优于标准治疗。在改善心力衰竭相关再入院率或死亡率方面的证据则不太一致,且 HBP 和 LBBAP 之间的效应大小存在差异。在导线测量和手术持续时间方面,LBBAP 优于 HBP。对于所有报告的结果,大型随机对照临床试验(RCT)的证据仍然很少。如果患者选择恰当且考虑到局限性,CSP 有可能可持续改善心脏起搏治疗的患者管理。通过本综述,我们不仅总结了现有数据,还展望了该领域未来可能的发展,并详细总结了即将进行的 RCT,这些 RCT 深入探讨了 CSP 的发展方向。